The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals
Abstract Alcohol use disorder (AUD) and methamphetamine use disorder (MUD) are prevalent and have high adverse impacts on both the individual and society. Current treatment strategies for these disorders are ineffective at a population level. Lorcaserin, a 5‐HT2C receptor agonist, has shown potentia...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | Pharmacology Research & Perspectives |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/prp2.767 |
| _version_ | 1830474184562573312 |
|---|---|
| author | Erin J. Campbell Yvonne Bonomo Adam Pastor Lisa Collins Amanda Norman Peter Galettis Janice Johnstone Andrew J. Lawrence |
| author_facet | Erin J. Campbell Yvonne Bonomo Adam Pastor Lisa Collins Amanda Norman Peter Galettis Janice Johnstone Andrew J. Lawrence |
| author_sort | Erin J. Campbell |
| collection | DOAJ |
| description | Abstract Alcohol use disorder (AUD) and methamphetamine use disorder (MUD) are prevalent and have high adverse impacts on both the individual and society. Current treatment strategies for these disorders are ineffective at a population level. Lorcaserin, a 5‐HT2C receptor agonist, has shown potential at reducing the symptoms of substance use disorder. This pilot study (initiated prior to market withdrawal) examined feasibility and safety of lorcaserin treatment in people undergoing residential detoxification and treatment for AUD and MUD. This was an open label pilot study of lorcaserin where participants (n = 10 AUD; n = 8 MUD) received 10‐mg lorcaserin daily for 4 days then twice daily for 1 month. Primary outcome measures included recruitment and retention rate, incidence of treatment‐emergent events, incidence of methamphetamine or alcohol withdrawal‐related events, heart rate, and blood pressure. Secondary measures included pharmacokinetic data and self‐reported alcohol or methamphetamine use, craving, and psychological distress. AUD participants were recruited faster and had a greater retention rate compared with MUD participants. Lorcaserin did not alter vital signs, was well tolerated, and had a similar pharmacokinetic profile to individuals with obesity. Lorcaserin reduced self‐reported alcohol and amphetamine‐type substance use and craving in AUD and MUD participants, respectively. Self‐reported psychological health also improved over the treatment period for all participants. Despite the pilot nature of this study, our data support the notion of 5‐HT2C receptors as a therapeutic target for drug and alcohol abuse. |
| first_indexed | 2024-12-21T15:14:29Z |
| format | Article |
| id | doaj.art-94a7b4f9ff654b3c8aab698a122701d8 |
| institution | Directory Open Access Journal |
| issn | 2052-1707 |
| language | English |
| last_indexed | 2024-12-21T15:14:29Z |
| publishDate | 2021-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj.art-94a7b4f9ff654b3c8aab698a122701d82022-12-21T18:59:11ZengWileyPharmacology Research & Perspectives2052-17072021-05-0193n/an/a10.1002/prp2.767The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individualsErin J. Campbell0Yvonne Bonomo1Adam Pastor2Lisa Collins3Amanda Norman4Peter Galettis5Janice Johnstone6Andrew J. Lawrence7Florey Institute of Neuroscience and Mental HealthMelbourne Brain CentreThe University of Melbourne Parkville VIC AustraliaDepartment of Addiction Medicine St Vincent's Hospital MelbourneThe University of Melbourne Parkville VIC AustraliaDepartment of Addiction Medicine St Vincent's Hospital MelbourneThe University of Melbourne Parkville VIC AustraliaDepartment of Addiction Medicine St Vincent's Hospital MelbourneThe University of Melbourne Parkville VIC AustraliaDepartment of Addiction Medicine St Vincent's Hospital MelbourneThe University of Melbourne Parkville VIC AustraliaSchool of Medicine and Public Health The University of Newcastle Callaghan NSW AustraliaSchool of Medicine and Public Health The University of Newcastle Callaghan NSW AustraliaFlorey Institute of Neuroscience and Mental HealthMelbourne Brain CentreThe University of Melbourne Parkville VIC AustraliaAbstract Alcohol use disorder (AUD) and methamphetamine use disorder (MUD) are prevalent and have high adverse impacts on both the individual and society. Current treatment strategies for these disorders are ineffective at a population level. Lorcaserin, a 5‐HT2C receptor agonist, has shown potential at reducing the symptoms of substance use disorder. This pilot study (initiated prior to market withdrawal) examined feasibility and safety of lorcaserin treatment in people undergoing residential detoxification and treatment for AUD and MUD. This was an open label pilot study of lorcaserin where participants (n = 10 AUD; n = 8 MUD) received 10‐mg lorcaserin daily for 4 days then twice daily for 1 month. Primary outcome measures included recruitment and retention rate, incidence of treatment‐emergent events, incidence of methamphetamine or alcohol withdrawal‐related events, heart rate, and blood pressure. Secondary measures included pharmacokinetic data and self‐reported alcohol or methamphetamine use, craving, and psychological distress. AUD participants were recruited faster and had a greater retention rate compared with MUD participants. Lorcaserin did not alter vital signs, was well tolerated, and had a similar pharmacokinetic profile to individuals with obesity. Lorcaserin reduced self‐reported alcohol and amphetamine‐type substance use and craving in AUD and MUD participants, respectively. Self‐reported psychological health also improved over the treatment period for all participants. Despite the pilot nature of this study, our data support the notion of 5‐HT2C receptors as a therapeutic target for drug and alcohol abuse.https://doi.org/10.1002/prp2.7675‐HT2C agonistalcoholcravinglorcaserinmethamphetamineserotonin |
| spellingShingle | Erin J. Campbell Yvonne Bonomo Adam Pastor Lisa Collins Amanda Norman Peter Galettis Janice Johnstone Andrew J. Lawrence The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals Pharmacology Research & Perspectives 5‐HT2C agonist alcohol craving lorcaserin methamphetamine serotonin |
| title | The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals |
| title_full | The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals |
| title_fullStr | The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals |
| title_full_unstemmed | The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals |
| title_short | The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals |
| title_sort | 5 ht2c receptor as a therapeutic target for alcohol and methamphetamine use disorders a pilot study in treatment seeking individuals |
| topic | 5‐HT2C agonist alcohol craving lorcaserin methamphetamine serotonin |
| url | https://doi.org/10.1002/prp2.767 |
| work_keys_str_mv | AT erinjcampbell the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT yvonnebonomo the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT adampastor the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT lisacollins the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT amandanorman the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT petergalettis the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT janicejohnstone the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT andrewjlawrence the5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT erinjcampbell 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT yvonnebonomo 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT adampastor 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT lisacollins 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT amandanorman 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT petergalettis 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT janicejohnstone 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals AT andrewjlawrence 5ht2creceptorasatherapeutictargetforalcoholandmethamphetamineusedisordersapilotstudyintreatmentseekingindividuals |